Hybridinoma Technology
Hybridinoma Technology
Hybridinoma Technology
TECHNOLOGY
HISTORY
o Developed by Georges
J.F. Kohler and Cesar
Milstein in 1975
o They shared nobel
prize for this
discovery in 1984
o The term hybridoma
was coined by Leonard
Herzenberg in 1975
o A hybridoma is a hybrid cell obtained by
fusion of B lymphocyte with usually a
tumor cell of antibody forming system
or B lymphocyte (these are called
myelomas)
PRINCIPLE
o The hybrid cell has the capacity of
antibody production derived from B
cells
o At the same time it can divide
continuously by the quality derived from
Myeloma cells
o By combining the desired qualities of
both the cells, the technology ensures
large scale Antibody production of
single specificity
o Specific hybridomas are either cultured
in vitro or passed through mouse
peritoneal cavity to obtain monoclonal
antibodies, this is called as hybridoma
technology
STEPWISE PROCEDURE
o Isolation of B cells
-Mice , 2-4 weeks old are immunized
with the antigen against which
monoclonal antibodies are to be raised
by subcutaneous injection
-Later B cells are isolated from the
spleen of an immunized mouse
o Isolation of myeloma cells
S
E
L
E
C
T
I
O
N
o Identification and isolation of the
hybridoma cells
• The first screening technique used is
ELISA
-Done by incubating the hybridoma
culture supernatant, secondary enzyme
labeled conjugate and chromogenic
substrate
-Formation of a coloured product
indicates a positive hybridoma
• Two methods have been used for
multiplying the hybridoma cells
1. In-vivo
2.In-vitro
In vivo
In
vitro
o Iv-vivo procedure involves introduction
of hybridoma cells into the peritoneal
cavity of the animal , then ascetic fluid
is isolated and then antibodies are
isolated from it
o In-vitro method involves culturing of
hybridoma cells in suitable culture
media and then antibodies are isolated
and purified
• Once a hybridoma colony is established,
it will continually grow in culture medium
like RPMI-1640 and produce antibodies
• Multiwell plates are used initially to
grow the hybridomas
• After selection, they are changed to
tissue culture flasks
• This provides enough cells for
cryopreservation and supernatant for
subsequent investigations
• The supernatant can yield 1 to
60micrograms per ml which can be
maintained at lower temperatures for
future use
THE TECHNOLOGY
• C:\Users\ADMIN\Desktop\monoclonalantibod
ies.mp4
RECENT ADVANCEMENTS
• availability of these antibodies with the
unmatched ability to identify highly
specific protein targets, has been
extensively exploited for both in vitro
diagnostics and in vivo therapeutics
• Monoclonal Antibody Development for
Quantitative Analysis of Pancreatitis
Associated Protein
• Immuno-PET: PET Imaging using
Radiolabeled Antibodies
REFERENCES
• B.D. Singh, Biotechnology Expanding
Horizones (3rd Revised edition) 2010,
Kalyani Publishers
• https://www.ncbi.nlm.nih.gov/pcm/articl
es/pm428445
• http://www.biologyexams4u.com
• http://www.biotecharticles.com/others-
article/hybridoma-technology
THANK YOU
oThe pancreatitis-associated protein (PAP) is a
pancreatic stress protein which is not produced in a
healthy pancreas but synthesized in high amounts in
pancreatic cells in response to acute and chronic
pancreatitis, hypoxia, toxins, diabetes and organ
transplant
oStrong induction of PAP observed during the early
phase of pancreatic diseases suggests that PAP
serum levels may be used as a valuable biological
marker. Pancreatic stress is among the symptoms of
Cystic Fibrosis (CF), so, PAP can also be used as a
marker of CF and numerous studies emphasize the
use of PAP in early diagnosis of CF in neonates
Positron Emission Tomography (PET) is a highly sensitive functional imaging
modality that provides 3-dimensional and quantifiable visualization of
biological processes.
Monoclonal Antibodies (mAbs) are high affinity molecules that can be used
for specific binding and delivery to cell surface molecules